Natural polymorphisms in HIV-1 CRF01_AE strain and profile of acquired drug resistance mutations in a long-term combination treatment cohort in northeastern China.
Abstract: The mutation rate at 14 sites increased significantly at TF time point compared to baseline, with the most common DRMs comprising G190S/C, K65R, K101E/N/Q, M184 V/I, and V179D/I/A/T/E, ranging from 66.7 to 45.2%.
Result: L228R was correlated with known DRMs Result: In this study, 40 out of 2034 (1.97%) treatment-naive CRF01_AE-infected patients had transmitted DRMs, with the common DRMs comprising K103 N, G190S, K101E, T215S, K65R, and K219Q.
Table: K65R
High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment.
PMID: 32105319
2020
The Journal of antimicrobial chemotherapy
Table: K65R
HIV-1 reverse transcriptase and protease mutations for drug-resistance detection among treatment-experienced and naive HIV-infected individuals.
Result: The most common primary NRTI mutations detected included M184V (62.04%), K65R (20.24%), K70R (15.01%), T215D/S (9.41%), Y115F (7.22%) and M41L (6.35%).
Table: K65R
Discussion: K65R is the signature mutation associated with TDF resistance.
Discussion: The most frequently identified ADR present in NRTI was M184V/I (61.27%), followed by K65R (19.96%).
Discussion: This study showed that K65R codon mutation had a significant increase from 2014 (71.4, 6.74, 16.42, 22.73%, 20.48 and 30.91%, respectiv
Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa.
Result: The K65R/N mutation occurred in five (5%) patients; K65R occurred in two (2%) patients receiving AZT plus 3TC, and in one (1%) patient receiving TDF plus FTC.
Table: K65R/N
Discussion: In our study, M184V, L74V, K65R, and Y115F were the most common major NRTI RAMs in patients receiving LPV/r as their bPIs.
Discussion: The K65R and Y115F RAMs occurred more frequently in patients receiving AZT plus 3TC, rather than in patients receiving ABC plus 3TC.
HIV-1 Drug Resistance, Distribution of Subtypes, and Drug Resistance-Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014-2016.
Result: The most commonly observed mutations with NRTIs were M184I/V (59.59%, 146/245), K65R (28.16%, 69/245), D67N/G (19.18%, 47/24
Discussion: NRTI-associated DRMs M184I/V and K65R and NNRTI-associated DRMs with extensively drug resistance K101E/H/P, V179I/D/E/T, Y181C/V, and G190A/E/K/Q/S/V were detected in CRF55_01B.
Discussion: K65R is one of the mutations with broad-spectrum resistance and was found in more than one-quarter of the cases.
Characteristics of drug resistance in HIV-1 CRF55_01B from ART-experienced patients in Guangdong, China.
PMID: 32300784
2020
The Journal of antimicrobial chemotherapy
Abstract: Among DRMs, M184V (43.83%) was the most frequent NRTI DRM, followed by K65R (23.46%), and V179E (98.77%) was the most frequent NNRTI DRM, followed by K103N (47.53%) and Y181C (14.81%).
The characteristics of pretreatment HIV-1 drug resistance in western Yunnan, China.
Abstract: Among the DRMs detected, some independently conferred resistance, such as K65R (1.6%, 5/322), Y188C/F/L (0.9%, 3/322), K103N (0.6%, 2/322) and G190A (0.3%, 1/322), which conferred high-level resistance.
Result: Among the key DRMs for NRTIs, K65R (1.6%, 5/322) conferred high-level resistance, T69D (0.3%, 1/322) conferred intermediate resistance and M41L (0.6%, 2/322), D67N (0.6%, 2/322) and T215D (0.3%, 1/322) conferred low-level resistance.
Discussion: Among the detected NRTI resistance mutations, K65R is a key mutation that causes intermediat
Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO).
Abstract: Baseline next-generation sequencing detected lamivudine resistance mutations (M184V/I and/or K65R/E/N) over a 5% threshold in 15/21 (71 4%) and 3/20 (15%) of partici
Result: Among participants without historical lamivudine resistance, none presented the K65R/E/N mutation but in three and seven cases the M184I mutation was detected with over a 5% or 1% threshold, respectively, including one participant harboring the M184I mutation with a 99% frequency.
Result: Seven participants with historical lamivudine resistance had the M184V/I and/or K65R/E/N mutations detected over the 20% threshold at baseline by next generation sequencing.
Table: K65R/E
Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development.
PMID: 32925358
2020
Journal of acquired immune deficiency syndromes (1999)
HIV mutation literature information.
PMID: 
2020
BMC infectious diseases
Browser Board
Co-occurred Entities
Filtrator
ViMRT